Please assess the completion status of the following clinical trial:

Trial Title: The Role of Metformin and Colesevelam in Human GLP-1 Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Normal hemoglobin~* BMI \> 23kg/m2~* HbA1c \<9 %~* Informed concent~Exclusion Criteria:~* Liver disease ( aspartate aminotransferase/alanine aminotransferase \>2 × reference value)~* Chronic intestinal disease~* History of liver and / or gallbladder disease~* Nephropathy (se-creatinine \>110 µM and / or albuminuria)~* Insulin or GLP-1-based antidiabetic treatment~* History of cholecystectomy or surgical resection of bowel segment~* BMI \<23kg/m2 or BMI \>35 kg/m2~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Colesevelam (Type: EXPERIMENTAL): None
- Metformin (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None
- Colesevelam + exendin (9-39) (Type: EXPERIMENTAL): None
- Metformin + exendin (9-39) (Type: EXPERIMENTAL): None
- Placebo + + exendin (9-39) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).